期刊
CURRENT DIABETES REPORTS
卷 15, 期 12, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-015-0692-4
关键词
Diabetes type 1; Cardiovascular; Lifestyle; Pediatrics
资金
- Johnson Johnson
- Eli Lilly
- Sanofi
- Novo Nordisk
- Roche
- Bristol-Myers Squibb/AstraZeneca
- Menarini
- Oshad
- Boehringer Ingelheim
- Dexcom
- Bayer
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in persons with type 1 diabetes (T1D). Specific risk factors associated with diabetes, such as hyperglycemia and kidney disease, have been demonstrated to increase the incidence and progression of CVD. Nevertheless, few data exist on the effects of traditional risk factors such as dyslipidemia, obesity, and hypertension on CVD risk in youth with T1D. Improvements in understanding and approaches to the evaluation and management of CVD risk factors, specifically for young persons with T1D, are desirable. Recent advances in noninvasive techniques to detect early vascular damage, such as the evaluation of endothelial dysfunction and aortic or carotid intima- media thickness, provide new tools to evaluate the progression of CVD in childhood. In the present review, current CVD risk factor management, challenges, and potential therapeutic interventions in youth with T1D are described.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据